Simulations Plus

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Simulations Plus reports Q1 revenue decline, eyes global expansion

Simulations Plus (SLP) navigated Q1 challenges with a focus on innovation, growth, and shareholder value.
Balancing revenue streams and exploring global opportunities position the company for future success.
Commitment to science, R&D, and market expansion underscores strategic vision and adaptability.
Positive outlook for future quarters driven by achievements, market traction, and evolving strategies.

Simulations Plus reports solid Q2 earnings, eyes growth opportunities

Simulations Plus delivered a strong quarter with revenue and net income growth.
The company's focus on collaborations and AI technologies bodes well for future growth.
Challenges in certain software products and economic impacts on sales cycles noted.
Opportunities in agrochemicals, biosimilars, and inorganic growth avenues are being pursued.

Simulations Plus (SLP) reports strong Q3 earnings and expands into oncology with Immunetrics acquisition

Simulations Plus (SLP) delivered a robust performance in Q3 2023, driven by revenue growth, strategic acquisitions, and operational initiatives.
While facing challenges such as renewal rate fluctuations, SLP remains well-positioned to capitalize on opportunities for growth and expansion.
Guidance for fiscal 2023, strong backlog visibility, and the Immunetrics acquisition underscore SLP's positive trajectory and potential for sustained success.

Simulations Plus (SLP) posts strong Q4 results, eyes biosimulation growth

Simulations Plus (SLP) delivered a solid performance in Q4 2023, showcasing revenue growth, strong margins, and notable achievements. While facing challenges from market conditions and nonrenewals, the company is optimistic about growth opportunities in biosimulation and revenue contributions from the Immunetrics acquisition.

Simulations Plus (SLP) reports stellar Q1 results and eyes growth

Simulations Plus (SLP) demonstrated robust performance across key segments, with strong revenue growth and profitability metrics.
While facing challenges like varied client budgets and revenue declines in certain units, the company is well-positioned to capitalize on growth opportunities.
With a focus on customer loyalty, operational efficiency, and strategic investments, Simulations Plus is poised for continued success in the market.

Simulations Plus (SLP) reports strong Q2 growth and outlook

Simulations Plus (SLP) demonstrated robust growth in Q2 2024
Strong performance in both Software and Services segments
Positive market outlook and strategic positioning for future growth
Focused on meeting fiscal 2024 guidance targets

Simulations Plus Reports Strong Q3, Eyes Growth Initiatives

Simulations Plus delivered a strong performance in Q3 2024, driven by growth in both software and services. The launch of new software and the acquisition of Pro-ficiency highlight strategic moves to enhance offerings and market position. However, challenges in gross margin and client spending patterns could impact future performance. Overall, the company remains focused on growth and operational integration.

Simulations Plus beats earnings expectations, eyes TAM expansion opportunities

Simulations Plus delivered strong financial results, exceeding revenue and EPS expectations. While facing challenges in meeting organic growth targets, the company's strategic investments and acquisitions position it well for future growth. With a focus on expanding TAM and maintaining profitability, Simulations Plus remains optimistic about its prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Tencent Music Entertainment Group 

Ternium

Epsilon Energy Ltd

Gulf Resources

Inmode Ltd

NuScale Power Corp

While it's a general rule of thumb that you get what you pay for, in the market, you can sneak in some overlooked compelling discounts, which might be the case with the below best affordable stocks to invest in. With a price tag under $50, these enterprises facilitate approachability while also delivering on the quality or relevance components.

7 Stocks Under $50 to Buy (and Never Sell)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today the release of a targeted package of software and services for accelerating pulmonary drug discovery and development.

Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes

Simulations Plus, Inc. is a company that develops software for drug discovery and development using artificial intelligence and machine learning technology. SLP has seen what was very impressive growth begin to quickly slow.

Simulations Plus: Overhyped With No Growth Left

Asure Software

Atlassian

Zscaler

Investors can consider adding four low-beta tech stocks like TEAM, ZS, SLP and ASUR in their portfolios to hedge against a highly-volatile market.

4 Low-Beta Tech Stocks to Hedge Against Market Uncertainty

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced the US FDA renewed licenses to DILIsym, its flagship QST software, ensuring the agency's continued access for another year.

Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses

The mean of analysts' price targets for Simulations Plus (SLP) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Can Simulations Plus (SLP) Climb 53.66% to Reach the Level Wall Street Analysts Expect?

Simulations Plus' (SLP) Q2 results are driven by higher revenues in Software and Services business segments.

Simulations Plus (SLP) Q2 Earnings Beat, Revenues Up Y/Y

Simulations Plus, Inc. (NASDAQ:SLP ) Q2 2023 Earnings Conference Call March 5, 2023 5:00 PM ET Company Participants Brian Siegel - Hayden IR Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financial Officer Conference Call Participants François Brisebois - Oppenheimer Matt Hewitt - Craig-Hallum Mitra Ramgopal - Sidoti Dane Leone - Raymond James Operator Greetings, and welcome to the Simulations Plus Second Quarter Fiscal 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Simulations Plus, Inc. (SLP) Q2 2023 Earnings Call Transcript

Simulations Plus (SLP) delivered earnings and revenue surprises of 11.11% and 2.54%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus (SLP) Surpasses Q2 Earnings Estimates

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reported revenue growth in the 2nd quarter of FY23 with total 2Q revenue up 6% to $15.8 million; YTD revenue up 2% to $27.7 million.

Simulations Plus Reports Second Quarter Fiscal 2023 Financial Results

Simulations Plus (SLP) will be working on the development of QSAR models by utilizing information available from both academic/patent literature and SACF to test effectiveness against MTHFD2.

Simulations Plus (SLP) Joins SACF to Develop Anticancer Drugs

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus collaborates with the Sino-American Cancer Foundation to use its AIDD technology & expertise to discover new anticancer therapies.

Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design Technology

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will host a webcast & conference call on April 5, 2023, at 5pm EDT to discuss the financial results from the 2nd quarter of FY2023.

Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference Call

Simulations Plus (SLP) noted that any intellectual property arising from the collaboration, will be jointly owned by Simulations Plus and IMB PAS.

Simulations Plus (SLP) Ties With IMB PAS for New Compounds

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn O'Connor will be presenting at the Sidoti Small-Cap Investor Conference taking place virtually on March 22-23, 2023.

Simulations Plus to Present at Sidoti March Small-Cap Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, using its AI/ML technologies in ADMET Predictor, will partner with the Polish Academy of Sciences to design novel lead molecules.

Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at Oppenheimer's 33rd Annual Healthcare Conference taking place virtually from March 13-15, 2023.

Simulations Plus to Present at Oppenheimer 33rd Annual Healthcare Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that management will be presenting at the Raymond James & Associates' 44th Annual Institutional Investors Conference, scheduled for March 5-8, 2023, at the JW Marriott Grande Lakes in Orlando, Florida.

Simulations Plus to Present at Raymond James 44th Annual Institutional Investors Conference

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered a new collaboration with a large agrochemicals company to extend the industry's top-rated machine learning model for the prediction of ionization constants (pKa) in the ADMET Predictor® platform.

Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning Models

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today announced the release of NAFLDsym v2B Beta, its QSP software tool redesigned to be faster, more intuitive, and more flexible.

Simulations Plus Releases Redesigned NAFLDsym® QSP Software Tool

Simulations Plus has been beaten down over the FY22' period to date, but has curled up off lows into the new year. It is a niche operator presenting with a differentiated offering for those speculating on clinical-stage assets.

Simulations Plus: Differentiated Offering For Speculators Of Clinical-Stage Assets

Simulations Plus' (SLP) latest DILIsym version X has a redesigned software infrastructure that includes server/cloud computing functionalities as well as command line and graphical interface options.

Simulations Plus (SLP) Rolls Out New Version of DILIsym

The ASR is a part of earlier announced (December 2022) $50 million share repurchase plan by Simulations Plus (SLP).

Simulations Plus (SLP) Announces $20M Accelerated Buyback Plan

FlexShares STOXX US ESG Impact Index Fund

LANCASTER, Calif.--( BUSINESS WIRE )--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division has released DILIsym® version X (DSX) Beta, the latest version of its flagship quantitative systems toxicology (QST) software for predicting and investigating drug-induced liver injury (DILI).

Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure

LANCASTER, Calif.--( BUSINESS WIRE )--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced it has entered into an accelerated share repurchase agreement (the “ASR Agreement”) with Morgan Stanley & Co. LLC. to repurchase an aggregate of $20 million of the Company's outstanding common shares. The ASR Agreement is part of the $50 million share repurchase program authorized by the Board of Directors on December 29, 2022. After completion of the repurchases under the ASR Agreement, $30 million will remain available for additional repurchases under the authorized repurchase program.

News for Simulations Plus Stock (SLP)